Is Brimonidine + Brinzolamide registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Brimonidine + Brinzolamide, including SIMBRINZA DROPS SUSP (2,10 mg/ml,mg/ml, Eye drops, suspension, SAR 64.60).

Is Brimonidine + Brinzolamide approved by the US FDA?

Drugs@FDA lists 1 application product line for Brimonidine + Brinzolamide, including SIMBRINZA (Prescription).

Is Brimonidine + Brinzolamide authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Brimonidine + Brinzolamide: Simbrinza.

Active substances

Brimonidine + Brinzolamide

SFDA 1
US FDA 1
EMA 1
Health Canada 1
US price lines 1
NHS prices 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
SIMBRINZA DROPS SUSP	2,10 mg/ml,mg/ml	Eye drops, suspension · Ocular use	1 Dropper Container	SAR 64.60	NCE · Prescription	NOVARTIS PHARMA AG	Valid

Indications — CHI Daman Drug Formulary

OPEN ANGLE GLUCOMA

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
SIMBRINZA	0.2%;1%	suspension/drops · ophthalmic	ALCON LABS INC	Prescription	19 Apr 2013

EMA European Union — centrally authorised medicines

Simbrinza Novartis Europharm Limited · Authorised · authorised 18 Jul 2014 · ATC S01EC54

Therapeutic indication (EMA)

Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction.

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
SIMBRINZA	02435411	1 % / W/V; 0.2 % / W/V	SUSPENSION · OPHTHALMIC	NOVARTIS PHARMACEUTICALS CANADA INC

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	SIMBRINZA 1%-0.2% EYE DROP	$26.03918	per ML	23 Sep 2026
NHS Drug Tariff	Brinzolamide 10mg/ml / Brimonidine 2mg/ml eye drops	£9.23	5 ml	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.